Summary
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PathologyReferences
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Cited 18 May 2014. http://globocan.iarc.fr/.
- Estimates of global cancer prevalence for 27 sites in the adult population in 2008.Int J Cancer. 2013; 132: 1133-1145
- HER2-positive gastric cancer.Gastric Cancer. 2014; 17: 1-12
- Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis.Arch Med Res. 2013; 44: 380-389
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.Br J Cancer. 2009; 100: 487-493
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697
- Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.Am J Surg Pathol. 2012; 36: 577-582
- Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.J Clin Oncol. 2013; 31: 4445-4452
- HER2 testing in gastric cancer: a practical approach.Mod Pathol. 2012; 25: 637-650
- Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force.Asia Pac J Clin Oncol. 2014; 10: 297-307
- HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible?.Diagn Cytopathol. 2015; 43: 80-85
- HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?.Pathology. 2014; 46: 184-187
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.Histopathology. 2011; 59: 832-840
- HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014; 27: 4-18
- Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers.Pathology. 2015; 47: 641-646
- Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.Hum Pathol. 2014; 45: 970-975
- Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.J Natl Cancer Inst. 2014; 106dju256
- Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.Diagn Mol Pathol. 2010; 19: 187-193
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study.Histopathology. 2008; 52: 797-805
Roche Products Pty Limited. Australian Herceptin (trastuzumab) Product Information. 2016; cited 24 Oct 2016. http://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropherce10315.
- Media Release. FDA approves Herceptin for HER2-positive metastatic stomach cancer.21 Oct 2010 (cited 7 Dec 2015)
- European Herceptin (trastuzumab) Product Information.2013 (Cited 7 Dec 2015)
- HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer.J Clin Pathol. 2012; 65: 751-757
- HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.Virchows Arch. 2010; 457: 299-307
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.J Clin Oncol. 2017; 35: 446-464
- Public Summary Document. Application No. 1163.1-Testing for HER2 status in gastric cancer for access to trastuzumab.2015 (cited 16 Feb 2017)
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.Nat Med. 2015; 21: 449-456
- Activating HER2 mutations in HER2 gene amplification negative breast cancer.Cancer Discov. 2013; 3: 224-237
- HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.Lung Cancer. 2015; 87: 14-22
- HER2 missense mutations have distinct effects on oncogenic signaling and migration.Proc Natl Acad Sci USA. 2015; 112: E6205-E6214
- A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.Pathology. 2017; 49: 38-43
- Prognostic significance of signet ring gastric cancer.J Clin Oncol. 2012; 30: 3493-3498
- Targeted HER2 treatment in advanced gastric cancer.Oncology. 2010; 78: 26-33
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.Ann Oncol. 2008; 19: 1523-1529
- HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.Diagn Pathol. 2013; 8: 76
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.Br J Cancer. 2011; 104: 1372-1376
- How many biopsy fragments will be necessary to assess HER2 status for gastric cancer?.J Clin Oncol. 2012; 30: 40
- Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.Oncotarget. 2015; 6: 38372-38380